Grünenthal

CompanyGermany

Grünenthal develops one asset, in phase 3 (testosterone undecanoate in hypogonadism). Mostly small molecule acting on AR; based in Germany.

1
Asset
Furthest: Phase 3; 3
Trials: 1
Signal

Pipeline

1

testosterone undecanoate
Provides sustained testosterone replacement, activating androgen receptors to restore androgen-dependent functions.
Phase 3, Small molecule, AR, hypogonadism, male hypogonadism

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials3
Signals1
Similar companies6

Papers

Diabetic Peripheral Neuropathy as a Risk Factor for Brain Disease
ADA Scientific Sessions 2025 abstract, 13 Jun 2025

Updated 11 Oct 2026 · 12 sources